. Author manuscript; available in PMC: 2016 May 1.

Published in final edited form as: Endocrine. 2014 Aug 17;49(1):231–241. doi: 10.1007/s12020-014-0383-y

Table 1.

Clinical baseline characteristics

Variable	Sparse GH	Dense GH	P value
Age (Mean ± SD)	40.4 ± 13.7	50.0 ± 12.8	0.0010
Gender (N: % Female)	16 (53.3%)	34 (47.9%)	0.62
Mean follow up (Yrs ± SD)	3.2 ± 2.3	2.4 ± 2.5	0.19
Tumor volume (mm³)^* Geo. Mean (95% CI)	2392, N=23 (1274-4537)	665, N=60 (428-1043)	0.0030
Cavernous sinus invasion N/N total (%)	12/23 (54.6%)	21/59 (35.6%)	0.12
Optic chiasm compression N/N total (%)	5/18 (21.7%)	8/59 (13.6%)	0.50
Baseline IGF-1 FC ULN Geo. Mean (95% CI)	2.80 (2.34-3.39)	2.88 (2.60-3.19)	0.80
Baseline GH level (ng/mL) Geo. Mean (95% CI)	9.77 (4.39-21.76)	11.59 (8.08-16.61)	0.54
GH index (GH baseline/tumor volume) Geo. Mean (95% CI)	0.0035 (0.0012-0.011)	0.019 (0.012-0.030)	0.013
Alpha subunit IHC expression N/N total (%)	2/30 (6%)	19/71 (40%)	0.0015
3-Month IGF-1 × FC ULN Geo. Mean (95% CI)	1.49 (1.15-1.95)	0.83 (0.70-0.98)	0.0007
3-Month GH level (ng/mL) Geo. Mean (95% CI)	3.42 (1.26-9.12)	0.64 (0.40-1.00)	0.0061
Ratio GH/IFG Geo Mean 95% CI	0.32 (0.11-0.90)	0.19 (0.098-0.36)	0.36

Tumor volume = 0.5 × (height × width × depth); FC ULN-fold change from upper limit of normal. Geo. (geometric) mean is the mean of the log values back transformed to the observed scale.